JP2022518778A5 - - Google Patents
Info
- Publication number
- JP2022518778A5 JP2022518778A5 JP2021543157A JP2021543157A JP2022518778A5 JP 2022518778 A5 JP2022518778 A5 JP 2022518778A5 JP 2021543157 A JP2021543157 A JP 2021543157A JP 2021543157 A JP2021543157 A JP 2021543157A JP 2022518778 A5 JP2022518778 A5 JP 2022518778A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962797743P | 2019-01-28 | 2019-01-28 | |
| US62/797,743 | 2019-01-28 | ||
| US201962931502P | 2019-11-06 | 2019-11-06 | |
| US62/931,502 | 2019-11-06 | ||
| PCT/US2020/015441 WO2020160010A1 (en) | 2019-01-28 | 2020-01-28 | Compounds and methods for the treatment of cystic fibrosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022518778A JP2022518778A (ja) | 2022-03-16 |
| JP2022518778A5 true JP2022518778A5 (https=) | 2023-02-01 |
| JPWO2020160010A5 JPWO2020160010A5 (https=) | 2023-02-01 |
Family
ID=71841934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543157A Pending JP2022518778A (ja) | 2019-01-28 | 2020-01-28 | 嚢胞性線維症の治療のための化合物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230055237A1 (https=) |
| EP (1) | EP3917516A4 (https=) |
| JP (1) | JP2022518778A (https=) |
| CN (1) | CN113613649A (https=) |
| WO (1) | WO2020160010A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR118050A1 (es) * | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| WO2022032062A1 (en) * | 2020-08-06 | 2022-02-10 | Carlex Glass America, Llc | Method of attaching a connector to a glazing |
| EP4029500A1 (en) * | 2021-01-15 | 2022-07-20 | Universidad Autónoma de Madrid | Tetrahydro-spiroindoline-pyrrolopyrrole-triones inhibitors of the nrf2-beta-trcp interaction for use in the treatment of nrf2-related diseases |
| RU2763141C1 (ru) * | 2021-06-29 | 2021-12-27 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | Этил (3r*,3a'r*,8a'r*,8b's*)-1',2,3'-триоксо-2',5-дифенил-1-(4-хлорфенил)-1,2,2',3',3a',6',7',8',8a',8b'-декагидро-1'h-спиро[пиррол-3,4'-пирроло[3,4-a]пирролизин]-4-карбоксилат, обладающий противомикробной активностью |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010006421A (es) * | 2007-12-10 | 2010-06-25 | Novartis Ag | Compuestos organicos. |
| WO2016201440A1 (en) * | 2015-06-12 | 2016-12-15 | The Regents Of The University Of California | Spiroindolinones and therapeutic uses thereof |
| WO2017117239A1 (en) * | 2015-12-30 | 2017-07-06 | Flatley Discovery Lab, Llc | Compounds and methods for the treatment of cystic fibrosis |
-
2020
- 2020-01-28 EP EP20747868.6A patent/EP3917516A4/en not_active Withdrawn
- 2020-01-28 WO PCT/US2020/015441 patent/WO2020160010A1/en not_active Ceased
- 2020-01-28 CN CN202080018339.8A patent/CN113613649A/zh active Pending
- 2020-01-28 JP JP2021543157A patent/JP2022518778A/ja active Pending
-
2021
- 2021-07-23 US US17/383,797 patent/US20230055237A1/en not_active Abandoned